# US 8,278,311 B2 · Substituted pyrimidine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,311 B2
- Document ID: US8278311B2
- Status: Granted
- Kind: B2
- Application number: 12/430,663
- Filed: 2009-04-27
- Published: 2009-10-29
- Granted: 2012-10-02
- Earliest claimed: 2008-04-28
- Assignees: Abbott Laboratories
- Inventors: Huaqing Liu; Irene Drizin; Marlon D. Cowart; Robert J. Altenbach
- Web page: https://patentgrep.com/patent/US8278311B2

## CPC

- C07D 491/048: the oxygen-containing ring being five-membered
- A61P 11/06: Antiasthmatics
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 239/70: condensed with carbocyclic rings or ring systems
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application describes substituted pyrimidine compounds of formula (I) wherein X, A1, R1, R2, R3, R4, R5, R6, R7, R8, R9, p, q, r, v, and w are defined in the specification, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable, salt, ester, or amide thereof, wherein
p is 1;
q is 0;
r is 0; and
X is O;
v and w are single or double bonds; with the proviso that w can be a single or a double bond when p is 1;
R1 is selected from hydrogen, —(C═O)—NH-alkylene(NR13R14), —(C═O)—(NR13R14), NH2, —NH(acyl), —NH(alkyl), —N(alkyl)2, —NH-alkylene-heteroaryl, —NH-alkylene(NR13R14), —NH(C═O)-alkylene(NR13R14), —NH(C═O)aryl, —NR13(C═O)NR13R14, —NHOH, —NHOCH3, —O-alkylene(NR13R14), alkoxy, alkoxycarbonyl, alkyl, carboxy, cyano, cyanoalkyl, cycloalkyl, fluoroalkyl, fluorocycloalkyl, hydroxyalkyl, and piperazine;
R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylsulfonyl, alkylthio, alkynyl, amido, aryl, carboxy, cyano, cyanoalkyl, cycloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, fluoroalkoxy, fluoroalkyl, fluorocycloalkyl, fluorocycloalkylalkyl, formyl, halogen, heteroaryl, heterocycle, hydrogen, hydroxy, hydroxyalkyl, mercapto, nitro, C(O)NR13R14, NR11COalkyl, —NR13R14, —N(R13)SO2(R14), —O-aryl, —O-heteroaryl, —S-aryl, and —SO2(NR13R14);
R2 and R4 together with the atom they are attached may form a ring, alternatively, any two of R2, R4, R6, and R8 that are on non-adjacent carbon atoms, may optionally be taken together to form a bridge selected from —CH═CH—, —CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—, or —CH2CH2CH2CH2CH2—;
R11 is selected from alkoxyalkyl, alkyl, cyanoalkyl, cycloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, fluoroalkyl, fluorocycloalkyl, fluorocycloalkylalkyl, hydrogen, and hydroxyalkyl;
R12 is selected from the group consisting of alkoxyalkyl, fluoroalkyl, fluorocycloalkyl, fluorocycloalkylalkyl, and hydroxyalkyl;
R13 and R14 are each independently selected from acyl, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfonyl, amido, aryl, cyanoalkyl, cycloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, fluoroalkyl, fluorocycloalkyl, fluorocycloalkylalkyl, formyl, heteroaryl, heterocycle, hydrogen, hydroxy, and hydroxyalkyl;
A1 is a group of structure A2 or A3
wherein A2 is
and A3 is selected from
wherein G1 is O, S, S(O), or S(O)2;
n is 1,2, or 3;
m is 0,1, or 2;
wherein each carbon atom of groups A1 may be optionally substituted with one or more groups selected from acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfonyl, alkylthio, alkynyl, amido, carboxy, cyano, cyanoalkyl, cycloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, fluorine, fluoroalkoxy, fluoroalkyl, fluorocycloalkyl, fluorocycloalkylalkyl, formyl, hydroxy, hydroxyalkyl, mercapto, and nitro.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is selected from hydrogen, NH2, NHOH, —NHOCH3, fluoroalkyl, cyanoalkyl, cycloalkyl, fluorocycloalkyl, hydroxyalkyl, cyano, and alkoxy.

### Claim 3 (depends on 1)

The compound of claim 1, wherein
v is a double bond;
w is a single bond;
R2 and R4 form a ring; and
R3 and R5 are hydrogen.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1 is NH2.

### Claim 5 (depends on 4)

The compound of claim 4, wherein A1 is a group of the formula

### Claim 6 (depends on 1)

The compound of claim 1, wherein
v is a double bond;
w is a double bond;
R2 and R4 form a ring; and
R3 and R5 are hydrogen.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R1 is NH2.

### Claim 8 (depends on 7)

The compound of claim 7, wherein A1 is a group of the formula

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is:
4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
4-[(3R)-3-(methylamino)pyrrolidin-1-yl]-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
(7aS,11aS)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
(7aR,11aR)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
4-(4-methyl-1,4-diazepan-1-yl)-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
4-(4-methylpiperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
4-[(3R)-3-aminopyrrolidin-1-yl]-7a,8,9,10,11,11a-hexahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
4-[(1R,5S)-3,6-diazabicyclo[3.2.0]hept-6-yl]-7a,8,9,10,11,11a-hexahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
4-(1,4-diazepan-1-yl)-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine;
4-(4-isopropyl-1,4-diazepan-1-yl)-5,6,7a, 8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine; and
4-(4-cyclobutyl-1,4-diazepan-1-yl)-5,6,7a, 8,9,10,11,11a-octahydro[1]benzofuro[2,3-h]quinazolin-2-amine.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
